A First in Human Phase I Randomized and Controlled Trial to Test Safety and Immunogenicity of a Multivalent Vaccine Against Neisseria Gonorrhoeae
The main goal of this trial is to evaluate the safety and immunogenicity of the candidate N. gonorrhoeae vaccine, LTB-NG6.
• Aged 18-50 years (inclusive) at the time of the first injection
• Good and stable general health, determined by medical history, laboratory findings and physical examination as judged by the Investigator before receiving the first injection.
• Willingness and ability to comply with the requirements of the protocol (e.g., completion of the diary forms, return for follow-up visits)
• Signed written informed consent obtained
• Availability for the trial duration, including all planned follow-up visits and phone calls
• Negative urine pregnancy test for WOCBP. WOCBP must be willing to use a highly effective method of contraception during the trial